



# Infectious Diseases Working Party

CHAIR: RAFAEL DE LA CAMARA

SECRETARY: DINA AVERBUCH

STATISTICIAN: GLORIA TRIDELLO

STUDY COORDINATOR LEAD: NINA KNELANGE

STUDY COORDINATOR: LOTUS WENDEL

DATA MANAGER: INGE VERHEGGE

## IDWP in 2021

### MAYOR ACHIEVEMENTS

This year, like 2020, was marked by the SARS-CoV-2 pandemic, impacting all aspects of HSCT, forcing historical changes like the universal cryopreservation of allogeneic products in many centres, decreasing the transplant activity for the first time in 30 years (6.5% in allogeneic HSCT and 7.5% in auto HSCT) (Passweg JR et al., BMT 2022 in press) and producing an important suffer for our patients with a high rate of mortality.

This year was also marked by the collaboration and generosity of the EBMT family and by a significant increase in the activity of the IDWP. The IDWP has participated in the elaboration of several recommendations and guidelines for this infection with other WPs and groups: the EBMT recommendations for the general management (16 updates) and vaccination of SARS-CoV-2 (8 updates); EBMT recommendations for HSCT in autoimmune diseases in the time of COVID-19 (in collaboration with ADWP, PWP, EBMT Nurses Group); and in the ECIL 9 COVID-19 guidelines (manuscript in preparation). Thanks to the generosity of several WPs of EBMT, an extra budget was obtained to support several studies under the umbrella of the recently created COVID Task Force.

But the activity of the IDWP has not been limited to SARS-CoV-2, and many other activities and studies have been done or are in progress. In 2021 we had 17 publications (Leukemia 2; Lancet Oncol 2; CID 1; J Infect 2; Ann Hematol 1, BMT 9) with the highest impact factor in the history of the group (168), and 4 communications to congresses (EBMT and ASH). We also organized two educational courses.

### EDUCATIONAL COURSES IN 2021

24rd IDWP educational (24 – 26 November 2021)

Covid-19 summit (29 June-1 July 2021)

### PRINCIPLE RESEARCH STUDIES

1) \*Impact of COVID-19 on stem cell transplant recipients and CAR-T cell recipients. *P. Ljungman* 2) Pulmonary function and GVHD before and after COVID-19 in transplant recipient survivors. *J.L. Piñana* 3) Impact of pre-existing invasive aspergillosis on allogeneic hematopoietic stem cell transplantation for treatment of acute leukemia and myelodysplastic syndrome. *O. Penack* 4) \*Influence of SARS-COV-2 pandemic on handling of allogeneic HPC grafts (IDWP/CTIWP study). *N. Worrel* 5) \*Central nervous system complications following hematopoietic stem cell transplantation. *M. Schmidt-Hieber* 6) \*Incidence and outcome of Adenovirus infections in patients who undergo haploidentical SCT. *M. Faraci*

\*= still recruiting

SEE ALL THE STUDIES ON: [www.ebmt.org/research/studies](http://www.ebmt.org/research/studies)

## Key Publications 2021

1. COVID-19 AND STEM CELL TRANSPLANTATION; RESULTS FROM AN EBMT AND GETH MULTICENTER PROSPECTIVE SURVEY.

*P. Ljungman. Leukemia. 2021;35(10):2885-94.*

2. SEASONAL HUMAN CORONAVIRUS RESPIRATORY TRACT INFECTION IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.

*J.L. Luis Piñana. J Infect Dis. 2021;223(9):1564-75.*

3. NOCARDIA INFECTIONS IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: A MULTICENTER INTERNATIONAL RETROSPECTIVE STUDY OF THE INFECTIOUS DISEASES WORKING PARTY (IDWP) OF THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION (EBMT).

*D. Averbuch. Clin Infect Dis Clin Infect Dis. 2021. Published online 1-Oct-2021. DOI: 10.1093/cid/ciab866*

4. EFFICACY, SAFETY AND FEASIBILITY OF TREATMENT OF CHRONIC HCV INFECTION WITH DIRECTLY ACTING AGENTS IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS - STUDY OF INFECTIOUS DISEASES WORKING PARTY OF EBMT.

*M. Mikulska. J Infect. 2022;84(1):71-9.*

5. ASSOCIATION OF PRE-EXISTING COMORBIDITIES WITH OUTCOME OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION. A RETROSPECTIVE ANALYSIS FROM THE EBMT.

*O. Penack. Bone Marrow Transplant. 2022;57(2):183-90.*

6. CONTRIBUTION OF NURSES TO PROTECTIVE ENVIRONMENT IN HEMATOPOIETIC CELL TRANSPLANT SETTING: AN INTERNATIONAL SURVEY BY THE EBMT.

*I. Agreiter. Bone Marrow Transplant DOI: 10.1038/s41409-020-01194-6.*

SEE ALL PUBLICATIONS ON: [www.ebmt.org/research/publications](http://www.ebmt.org/research/publications)

## IDWP in 2022

### STUDIES STARTING SOON

**COVID-19 STUDIES:** 1) Cryopreservation in allo-HSCT during COVID-19 pandemic, 2) Prolonged shedding of SARS-CoV-2 infection, 3) Cycle threshold values, 4) Pulmonary imaging

**NON-COVID RETROSPECTIVE:** 1) Infections after HCT in patients with preexisting diabetes mellitus, 2) Non-Tuberculous Mycobacterial Infections post-HSCT 3) Fusarium infections in HSCT recipients, 4) Survey on the use of non-cryopreserved hematopoietic stem cells for auto-HSCT

**NON-COVID PROSPECTIVE:** Viral infections after unmanipulated allo-HSCT in pediatric patients.

### IDWP AT 47<sup>TH</sup> ANNUAL MEETING OF EBMT (VIRTUAL):

#### **IDWP BUSINESS MEETING**

MONDAY, MARCH 21, 07:00-08:50

#### **IDWP WP SESSION**

MONDAY, MARCH 21, 09:00-10:15

1. THE MOST IMPORTANT ARTICLES ON INFECTIONS IN HSCT RECIPIENTS. *M. MIKULSKA*
2. WHATS NEW IN THE FIELD OF ANTIFUNGALS?. *J. MAERTENS*
3. IS ANTIBACTERIAL/ANTIFUNGAL/ANTIVIRAL PROPHYLAXIS NEEDED IN CART? *L. GIL*

#### **ORAL PRESENTATIONS:**

1. *J. Styczynski* - Causes of deaths after hematopoietic cell transplantation in the context of lethal infectious complications: IDWP EBMT COD-2 study (OS04-01)
2. *D. Averbuch* - Listeria infection in hematopoietic cell transplant recipients: an international case-control study of the IDWP of the EBMT (OS04-02)
3. *J. L. Pinana* - Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic stem cell transplantation (OS04-08)

#### **OTHER INFECTIOUS RELATED SESSIONS**

- 1) Therapy of fungal infections (MTE-02; Meet the expert). *D. Averbuch*; 17:00-18:00
- 2) Mycobacterial infections (MTE-03; Meet the expert). *A. Bergeron*; 17:00-18:00
- 3) NG06 – Infections
- 4) Novel viral infections in immunocompromised patients (MTE-09). *M. Von Lilienfeld-Toal*; 17:45-18:45
- 5) COVID-19 in HCT candidates and patients in the post-vaccine era (MTE-14). *P. Ljungman*
- 6) OS04 - Oral session 4: Infectious complications I
- 7) OS06 - Oral session 6: Infectious complications II, COVID
- 8) W6 - Can we limit infectious complications in transplant setting?
- 9) E11 - CMV – still a challenge?
- 10) E12 - Update on viral infections in the transplant setting
- 11) SS2 - COVID-19
- 12) NG17 – COVID

#### **POSTERS:**

- 1) Handling of allogeneic related and unrelated HPC grafts during the covid-19 pandemic – a survey from the IDWP and CTIWP
- 2) The management of cytomegalovirus infection among EBMT centers: a survey from IDWP of EBMT
- 3) Outcome of post-vaccination covid-19 in HSCT and CAR T cell treatment recipients; results from an IDWP prospective survey.

### EDUCATIONAL ACTIVITIES IN 2022

25th IDWP Educational Course –November 3-5, Florance, Italy

## Contact the IDWP

For participation in, or information regarding IDWP studies, please contact us at

[idwp.ebmt@lumc.nl](mailto:idwp.ebmt@lumc.nl)




Rafael de la Camara  
IDWP CHAIR  
SPAIN



Dina Averbuch  
SECRETARY IDWP  
ISRAEL




Gloria Tridello  
IDWP BIostatistician  
VERONA, ITALY



Nina Knelange  
IDWP STUDY COORDINATOR  
LEIDEN, NETHERLANDS



Lotus Wendel  
IDWP DATA MANAGER  
LEIDEN, NETHERLANDS



Inge Verheggen  
IDWP DATA MANAGER  
LEIDEN, NETHERLANDS

FIND MORE INFO ON: [ebmt.org/working-parties/infectious-diseases-working-party-idwp](http://ebmt.org/working-parties/infectious-diseases-working-party-idwp)